Amarin Corporation plc

Equities

AMRN

US0231112063

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-18 pm EDT 5-day change 1st Jan Change
0.8718 USD -4.94% Intraday chart for Amarin Corporation plc -14.53% +0.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
Amarin Corporation plc Announces New Reduce-It® Analyses Show Vascepa®/Vazkepa® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups CI
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday MT
European Equities Traded in the US as American Depositary Receipts Start Week Slightly Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Decline Tuesday MT
European Equities Traded in the US as American Depositary Receipts Rise Monday Afternoon MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading But End Week Flat MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading MT
Transcript : Amarin Corporation plc, Q4 2023 Earnings Call, Feb 29, 2024
Amarin Corporation plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Amarin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 Revenue $74.7M, vs. Street Est of $71.1M MT
Earnings Flash (AMRN) AMARIN CORPORATION Posts Q4 EPS $-0.01, vs. Street Est of $-0.03 MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly in Tuesday Trading MT
Chart Amarin Corporation plc
More charts
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
0.8718 USD
Average target price
1.083 USD
Spread / Average Target
+24.26%
Consensus
  1. Stock Market
  2. Equities
  3. AMRN Stock
  4. News Amarin Corporation plc
  5. JPMorgan Downgrades Amarin to Underweight From Neutral